Xinludi Pharmaceutical

Xinludi Pharmaceutical (Qingdao) Co., Ltd., a subsidiary of 3D Medicines Inc., is a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative oncology therapies. The company is a key participant in the development of 3D189 (galinpepimut-S), a WT1-targeting peptide vaccine currently in Phase 3 clinical trials for acute myeloid leukemia. Its parent organization, 3D Medicines, is well-known for the commercialization of envafolimab (Envada), the world's first subcutaneous PD-L1 inhibitor. Xinludi leverages advanced technology platforms, including AI-driven drug discovery and mRNA-based vaccine development, to address unmet medical needs in cancer treatment. The company maintains significant R&D and manufacturing capabilities in China, operating as a core entity within the 3D Medicines group.